Ken Griffin Astria Therapeutics, Inc. Put Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q2 2024 Aug 14, 2024	SELL	$8.83 - $13.51 $309,050 - $472,850	-35,000 Reduced 56.27%	27,200 $247,000
Q1 2024 May 15, 2024	BUY	$6.99 - $16.69 $431,283 - $1.03 Million	61,700 Added 12340.0%	62,200 $875,000
Q4 2023 Feb 14, 2024	SELL	$4.42 - $8.06 $2,652 - $4,836	-600 Reduced 54.55%	500 $3,000
Q3 2023 Nov 14, 2023	SELL	$6.89 - $9.86 $30,316 - $43,384	-4,400 Reduced 80.0%	1,100 $8,000
Q2 2023 Aug 14, 2023	BUY	$8.33 - $13.72 $32,487 - $53,508	3,900 Added 243.75%	5,500 $45,000
Q1 2023 May 15, 2023	SELL	$11.2 - $15.79 $116,479 - $164,216	-10,400 Reduced 86.67%	1,600 $21,000
Q4 2022 Feb 14, 2023	BUY	$7.44 - $14.89 $89,280 - $178,680	12,000 New	12,000 $178,000

105

49.6M

27.6K

29.7K

Ticker ATXS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 15,178,000
Market Cap $179M
Description
Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.